脊髓性肌萎缩症的诊断和治疗研究进展OA
Research advances in the diagnosis and treatment of spinal muscular atrophy
脊髓性肌萎缩症(spinal muscular atrophy,SMA)是一种罕见的由运动神经元存活1(survival motor neuron 1,SMN1)基因致病性变异所致的运动神经元病,核心临床表现为进行性骨骼肌无力和肌萎缩,具有致残、致死性.随着机制研究和药物研发的不断突破,SMA的早期识别甚至症状前诊断成为可能,疾病修正治疗真正可及,根治性基因疗法也已取得突破性进展.本文系统阐述SMA的诊疗进展,以期提高对其的认识,有利于疾病的规范化诊疗.
Spinal muscular atrophy(SMA)is a rare motor neuron disease caused by pathogenic variants in the survival motor neuron 1(SMN1)gene.The primary clinical manifestations include progressive muscle weakness and atrophy,which can lead to disability and even death.With ongoing breakthroughs in understanding the disease mechanism and drug development,early identification and presymptomatic diagnosis of SMA have become possible.Disease-modifying treatments are increasingly accessible and significant progress has been made in curative gene therapy.This article systematically reviews recent advances in the diagnosis and treatment of SMA,aiming to enhance understanding and promote standardization.
吴莹;魏翠洁
北京大学第一医院儿童医学中心,北京 102600北京大学第一医院儿童医学中心,北京 102600
脊髓性肌萎缩症早期诊断疾病修正治疗基因疗法
Spinal muscular atrophyEarly diagnosisDisease-modifying treatmentGene therapy
《中国医学前沿杂志(电子版)》 2026 (2)
22-29,8
National Natural Science Foundations of China(82402177)National High Level Hospital Clinical Research Funding(Interdepartmental Research Project of Peking University First Hospital,2023IR51)Beijing High-Level Innovation and Entrepreneurship Talent Support Program-Healthcare Platform young backbonetalent projects(G202531202) 国家自然科学基金(82402177)中央高水平医院临床科研业务费资助(北京大学第一医院院内交叉研究专项,2023IR51)北京高层次创新创业人才支持计划"医疗卫生平台"青年骨干人才(G202531202)
评论